Technology
Health
Biotechnology

Motif Bio

$1.83
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (5.84%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Motif Bio and other stocks, options, ETFs, and crypto commission-free!

About

Motif Bio plc ADRs, also called Motif Bio, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Read More It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ.

Employees
Headquarters
Princeton, New Jersey
Founded
2014
Market Cap
25.65M
Price-Earnings Ratio
Dividend Yield
Average Volume
195.69K
High Today
$1.94
Low Today
$1.74
Open Price
$1.74
Volume
19.24K
52 Week High
$11.45
52 Week Low
$1.54

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Gold
Metals

News

Seeking AlphaMay 22

Motif Bio to evaluate iclaprim in ophthalmology; shares up 8% premarket

Motif Bio (NASDAQ:MTFB) has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in vitro model of ocular toxoplasmosis.

107
NasdaqMay 3

Motif Bio meeting with U.S. FDA held as planned

NEW YORK, May 03, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, confirms that the Company met with the U.S. Food & Drug Administration (FDA) on May 3, 2019 as expected. The Type A meeting was held to discuss the points raised in the Complete Response Letter received from the FDA related to the New Drug Application (NDA) for iclaprim for the treatment of acute bacterial skin and skin structure infections....

425
Markets InsiderApr 26

Motif Bio plc: Notice of Annual General Meeting

181
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.